Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
Siteman Cancer Center at Barnes-Jewish St. Peters Hospital - Saint Louis
mi
from
St Louis, MO
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
Siteman Cancer Center at Barnes-Jewish St. Peters Hospital - Saint Louis
mi
from
St Louis, MO
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
Mount Sinai Hospital
mi
from
New York, NY
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated:  7/30/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma
Status: Enrolling
Updated: 7/30/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated:  7/31/2015
U.S. Medical Information
mi
from
Rockland, MA
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated: 7/31/2015
U.S. Medical Information
mi
from
Rockland, MA
Click here to add this to my saved trials
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated:  7/31/2015
Merck KGaA Communication Center
mi
from
Darmstadt,
Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials
Status: Enrolling
Updated: 7/31/2015
Merck KGaA Communication Center
mi
from
Darmstadt,
Click here to add this to my saved trials
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine
Status: Enrolling
Updated:  8/4/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine
Status: Enrolling
Updated: 8/4/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine
Status: Enrolling
Updated:  8/4/2015
VA Puget Sound Health Care System
mi
from
Seattle, WA
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine
Status: Enrolling
Updated: 8/4/2015
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine
Status: Enrolling
Updated:  8/4/2015
University of Rochester
mi
from
Rochester, NY
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine
Status: Enrolling
Updated: 8/4/2015
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine
Status: Enrolling
Updated:  8/4/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine
Status: Enrolling
Updated: 8/4/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
FDG-PET/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients
FDG-PET/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients
Status: Enrolling
Updated:  8/4/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
FDG-PET/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients
FDG-PET/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients
Status: Enrolling
Updated: 8/4/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
Status: Enrolling
Updated:  8/4/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
Status: Enrolling
Updated: 8/4/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma
Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma
Status: Enrolling
Updated:  8/4/2015
University Of Alabama At Birmingham Hospital
mi
from
Birmingham, AL
Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma
Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma
Status: Enrolling
Updated: 8/4/2015
University Of Alabama At Birmingham Hospital
mi
from
Birmingham, AL
Click here to add this to my saved trials
Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia
Treatment of Acute Myelogenous Leukemia With Busulfan and Etoposide Followed by Autologous or Syngeneic Stem Cell Rescue and Low-Dose Interleukin 2 (IL-2) Immunotherapy
Status: Enrolling
Updated:  8/4/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia
Treatment of Acute Myelogenous Leukemia With Busulfan and Etoposide Followed by Autologous or Syngeneic Stem Cell Rescue and Low-Dose Interleukin 2 (IL-2) Immunotherapy
Status: Enrolling
Updated: 8/4/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated:  8/5/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated: 8/5/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Status: Enrolling
Updated:  8/5/2015
Beckman Laser Institute, Unversity of California Irvine
mi
from
Irvine, CA
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Status: Enrolling
Updated: 8/5/2015
Beckman Laser Institute, Unversity of California Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  8/7/2015
Massachusetts General Hospital
mi
from
Boston, MA
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 8/7/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  8/7/2015
Dana Faber Cancer Institute
mi
from
Boston, MA
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 8/7/2015
Dana Faber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  8/7/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 8/7/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  8/7/2015
Memorial Sloan-Kettering Cancer Centre
mi
from
New York, NY
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 8/7/2015
Memorial Sloan-Kettering Cancer Centre
mi
from
New York, NY
Click here to add this to my saved trials
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  8/7/2015
MCW and Froedtert Clinical Cancer Center, Division of Neoplastic Diseases & Related Disorders
mi
from
Milwaukee, WI
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 8/7/2015
MCW and Froedtert Clinical Cancer Center, Division of Neoplastic Diseases & Related Disorders
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Washington University School of Medicine
mi
from
Saint Louis, MO
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Weill-Cornell Medical College
mi
from
New York, NY
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/10/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/10/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Boston, MA
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
St. Louis, MO
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Houston, TX
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  8/10/2015
mi
from
Toronto,
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 8/10/2015
mi
from
Toronto,
Click here to add this to my saved trials
Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant
Pilot Trial of Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant
Status: Enrolling
Updated:  8/11/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant
Pilot Trial of Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant
Status: Enrolling
Updated: 8/11/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Therapeutic Research in Multiple Myeloma
UARK 91-004 Therapeutic Research in Multiple Myeloma
Status: Enrolling
Updated:  8/12/2015
University of Arkansas for Medical Sciences/MIRT
mi
from
Little Rock, AR
Therapeutic Research in Multiple Myeloma
UARK 91-004 Therapeutic Research in Multiple Myeloma
Status: Enrolling
Updated: 8/12/2015
University of Arkansas for Medical Sciences/MIRT
mi
from
Little Rock, AR
Click here to add this to my saved trials
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  8/12/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 8/12/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
A Phase II/III, Randomized, Cross-over, Open-label Trial to Demonstrate Superiority of Prophylaxis Over On-demand Therapy in Previously Treated Subjects With Severe Hemophilia A Treated With Plasma Protein-free Recombinant FVIII Formulated With Sucrose (BAY 81-8973)
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Dayton, OH
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
A Phase II/III, Randomized, Cross-over, Open-label Trial to Demonstrate Superiority of Prophylaxis Over On-demand Therapy in Previously Treated Subjects With Severe Hemophilia A Treated With Plasma Protein-free Recombinant FVIII Formulated With Sucrose (BAY 81-8973)
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials